ArticleWorld journal of surgery2022
Management of Granulomatous Lobular Mastitis and Risk Factors Associated with Recurrence.
Article in World journal of surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Granulomatous mastitis, erythema nodosum, and arthritis syndrome: a narrative review.Frontiers in immunology · 2025Pooled it
- Idiopathic granulomatous mastitis in the United Arab Emirates: a retrospective case series of clinical features, management, and outcomes.Clinical rheumatology · 2026Article
- Article
- An endocrine microbe immunity framework for granulomatous mastitis toward phenotype-oriented interpretation.iScience · 2026Review
- Case Report: Staged topical herbal therapy for giant plasma cell mastitis in pregnancy with 3-year follow-up.Frontiers in medicine · 2026Article
- Treatment Outcomes of Lobular Granulomatous Mastitis: Impact of Hyperprolactinemia, Diabetes, and Erythema Nodosum-Insights From a 7-Year Cohort Study.The breast journal · 2026Article
- Analysis of risk factors associated with recurrence of granulomatous lobular mastitis and establishment of a prediction model.Discover oncology · 2025Article
- Clinical Characteristics of Non-Lactational Mastitis of Accessory Breast: A Case-Series Study.International journal of women's health · 2025Article
- Article
- Article
- Exploring the interplay of prolactin and bromocriptine on serum markers in granulomatous lobular mastitis.Frontiers in immunology · 2025Article
- Long-Term Outcomes of Traditional Chinese Medicine in the Treatment of Granulomatous Lobular Mastitis: A Two-Year Follow-Up Study on Recurrence and New Occurrence Rates with Analysis of Risk Factors.Journal of inflammation research · 2024Article
- The Predictive Value of Preoperative Systemic Immune-Inflammation Index in Patients with Granulomatous Mastitis.Journal of inflammation research · 2024Article
- Predisposing Factors for Granulomatous Lobular Mastitis: A Case-Control Study.International journal of women's health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGranulomatous lobular mastitis (GM), an inflammatory breast lesion with unknown etiology, is prone to recur. There is no global consensus on the optimal treatment at present. This study was conducted to show our step-by-step systemic procedure and discuss the recurrence risk factors of GM.
methodsThe medical record database was retrospectively searched for patients with GM treated in our hospital between January 2015 and September 2021. Patients were divided into non-recurrence group (group A) and recurrence group (group B). Demographic and clinical characteristics, treatment and follow-up were collected and analyzed.
resultsA total of 885 GM patients were included in our study, all of whom received step-by-step systemic management. The mean age was 33.2 ± 5.2 years. There were 760 (85.9%) patients in group A and 125 (14.1%) in group B. Univariate analysis showed that there was no statistically significant difference between the two groups in size of mass, pregnancy, hyperprolactinemia, bacterial cultures, erythema nodosum. Multivariate analysis showed that patients with purulent nipple discharge, skin lesion, bilateral disease and patients who need the combination of surgery and medication to achieve complete remission had higher risk of recurrence.
conclusionsWe built a step-by-step systemic procedure for GM, and the recurrence rate was 14.1%. Prolactin level and microbiological results are important for the management of GM. Purulent nipple discharge, skin lesion, bilateral disease and patients who need the combination of surgery and medication to achieve complete remission are associated with GM recurrence. Prolonged maintenance therapy may secure a better prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.